Research
Hormonal
Further pharmacological options, such as dual and triple incretins, are probable forthcoming additions to clinical practice.
Practitioners should stay informed about new pharmacological options for obesity management.
GoodSupportsmedium confidence
Further pharmacological options, such as dual and triple incretins, are probable forthcoming additions to clinical practice.
Why this rating
The claim is based on the review of current and upcoming medications.
Source
Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks
Camille Lupianez‐Merly et al. · Alimentary Pharmacology & Therapeutics · 2024
DOI 10.1111/apt.17856
reviewCited 35×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →